The lineup includes the Wegovy pill (oral semaglutide, FDA-approved December 2025, launched January 2026, the first FDA-approved oral GLP-1 for weight loss in adults), the Wegovy pen (injectable semaglutide 2.4 mg), Zepbound (tirzepatide via LillyDirect), and Ozempic (off-label for weight loss)
How to Stop GLP-1 Safely If you are considering stopping GLP-1 medication, discuss this with your prescriber first
However, dietary cholesterol is common in foods that are high in harmful saturated fats
Novo Nordisk (NVO) Trailing P/Es: LLY 38, NOV 10 Forward P/Es: LLY 26, NVO 11 Estimated 2026 sales growth: LLY 26%, NVO -8% Estimated 2025 EPS growth: LLY 43%, NVO -6% Cash per share: LLY $8.14, NVO $6.07 Institutional ownership: LLY 84.6%, NVO 9.5% In terms of value, NVO has LLY beat by a mile, trading at less than a third of LLY on a trailing price-to-earnings basis and just under half of it on a forward price-to-earnings basis
At the American Society of Clinical Oncologys annual meeting in Chicago, researchers presented three large observational studies on GLP-1 drugssuch as Ozempic, Wegovy, Mounjaro and Zepbound
Probiotics are known to support gut health and may indirectly support GLP-1 levels
.webp)
